The current status and future prospects of precision medicine
-
Maria D. Pasic
Abstract
Over the last 5 years I have been coordinating a graduate course on genomic technologies and their applications in medicine. The course is offered to graduate students in the Department of Laboratory Medicine and Pathobiology at the University of Toronto. In attending the diverse lectures, I came to better understand the burgeoning field of “personalized” or “precision” medicine (PM) and its current status and future prospects. Below, I provide my personal views on this topic.
Author contributions: The author has accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
References
1. Pulciani S, Di Lonardo A, Fagnani C, Taruscio D. P4 medicine versus Hippocrates. Ann 1st Super Sanita 2017;53:185–91.Search in Google Scholar
2. Goldman JM, Galey GQ. Chronic myelogenous leukemia-a brief history. In: Myeloproliferative disorders. Hematologic malignancies. Berlin: Springer, 2007:1–13.10.1007/978-3-540-34506-0Search in Google Scholar
3. Balachandran VP, DeMatteo RP. GIST tumors: who should get imatinib and for how long? Adv Surg 2014;48:165–83.10.1016/j.yasu.2014.05.014Search in Google Scholar
4. Anonymous. A triumph of perseverance over interference. Nat Biotechnol 2018;36:775.10.1038/nbt.4255Search in Google Scholar
5. Rittenhouse H, Blasé A, Shamel B, Schalken J, Groskopf J. The long and winding road to FDA approval of a novel prostate cancer test: our story. Clin Chem 2013;59:32–4.10.1373/clinchem.2012.198739Search in Google Scholar
6. Sheridan C. Roche splashes $2.4 billion on Foundation Medicine’s cancer platform. Nat Biotechnol 2018;36:779–80.10.1038/nbt0918-779Search in Google Scholar
7. Liu YC, Ma Y, An N, Sun P, Wang Y, Sun C. Clinical efficacy of combination of pertuzumab, trastuzumab, and docetaxel for treatment of patients with HER2-positive breast cancer. Medicine (Baltimore) 2019;98:e17262.10.1097/MD.0000000000017262Search in Google Scholar
8. Le Tourneau C, Delord JP, Gonçalves A, Gavoille C, Dubot C, Isambert N, et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol 2015;16:1324–34.10.1016/S1470-2045(15)00188-6Search in Google Scholar
9. Marquart J, Chen EY, Prasad V. Estimation of the percentage of US patients with cancer who benefit from genome-driven oncology. J Am Med Assoc Oncol 2018;4:1093–8.10.1001/jamaoncol.2018.1660Search in Google Scholar PubMed PubMed Central
10. Zehir A, Benayed R, Shah R, Syed A, Middha S, Kim HR, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med 2017;23:703–13.10.1038/nm.4333Search in Google Scholar PubMed PubMed Central
11. Bian S, Hou Y, Zhou X, Li X, Yong J, Wang Y, et al. Single-cell multiomics sequencing and analyses of human colorectal cancer. Science 2018;362:1060–3.10.1126/science.aao3791Search in Google Scholar PubMed
12. Senn S. Statistical pitfalls of personalized medicine. Nature 2018;563:619–21.10.1038/d41586-018-07535-2Search in Google Scholar PubMed
13. Allison J. Quoted in Nat Biotechnol 2018;36:781. https://www.biocentury.com/bc-innovations/tools-techniques/2018-07-19/how-md-anderson-using-its-access-clinical-samples-home-.10.1038/nbt0918-781bSearch in Google Scholar PubMed
14. Robert C, Ribas A, Hamid O, Daud A, Wolchok JD, Joshua AM, et al. Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma. J Clin Oncol 2018;36:1668–74.10.1200/JCO.2017.75.6270Search in Google Scholar PubMed
15. Aggrawal A, Ginsburg O, Fojo T. Cancer economics, policy and politics: What informs the debate? Perspectives from the EU, Canada and US. J Cancer Policy 2014;2:1–11.10.1016/j.jcpo.2014.02.002Search in Google Scholar
16. Song M, Vogelstein B, Giovannucci EL, Wilett WC, Tomasetti C. Cancer prevention: Molecular and epidemiologic consensus. Science 2018;361:1317–8.10.1126/science.aau3830Search in Google Scholar PubMed PubMed Central
17. Rodland KD, Piehowski P, Smith RD. Moonshot objectives: Catalyze new scientific breakthroughs-Proteogenomics. Cancer J 2018;24:121–5.10.1097/PPO.0000000000000315Search in Google Scholar PubMed PubMed Central
18. Walker SP. The ROC curve redefined-optimizing sensitivity (and specificity) to the lived reality of cancer. N Engl J Med 2019;380:1594–5.10.1056/NEJMp1814951Search in Google Scholar PubMed
©2020 Walter de Gruyter GmbH, Berlin/Boston
Articles in the same Issue
- Frontmatter
- Editorial
- Measurement uncertainty: light in the shadows
- Review
- Childhood obesity: an overview of laboratory medicine, exercise and microbiome
- Mini review
- The utility of measurement uncertainty in medical laboratories
- Opinion Paper
- Do genetic polymorphisms in angiotensin converting enzyme 2 (ACE2) gene play a role in coronavirus disease 2019 (COVID-19)?
- Opinion Papers
- The current status and future prospects of precision medicine
- Precision medicine in medical oncology: hope, disappointment and reality
- IFCC Papers
- Laboratory practices to mitigate biohazard risks during the COVID-19 outbreak: an IFCC global survey
- Operational considerations and challenges of biochemistry laboratories during the COVID-19 outbreak: an IFCC global survey
- Genetics and Molecular Diagnostics
- Diverse fragment lengths dismiss size selection for serum cell-free DNA: a comparative study of serum and plasma samples
- General Clinical Chemistry and Laboratory Medicine
- Quantification of plasma remdesivir and its metabolite GS-441524 using liquid chromatography coupled to tandem mass spectrometry. Application to a Covid-19 treated patient
- Isotope dilution-LC-MS/MS method for quantification of the urinary cotinine-to-creatinine ratio
- A liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based assay to profile 20 plasma steroids in endocrine disorders
- Assessment of antinuclear antibodies by indirect immunofluorescence assay: report from a survey by the American Association of Medical Laboratory Immunologists
- Evaluation of a novel extended automated particle-based multi-analyte assay for the detection of autoantibodies in the diagnosis of primary biliary cholangitis
- Reference Values and Biological Variations
- Continuous, complete and comparable NT-proBNP reference ranges in healthy children
- Reference-mean-centered statistical quality control
- Hematology and Coagulation
- Top-down and bottom-up approaches for the estimation of measurement uncertainty in coagulation assays
- Cancer Diagnostics
- Tumor-associated exosomal miRNA biomarkers to differentiate metastatic vs. nonmetastatic non-small cell lung cancer
- Analysis of EGFR mutation status in malignant pleural effusion and plasma from patients with advanced lung adenocarcinoma
- Cardiovascular Diseases
- Establishing the 99th percentile of a novel assay for high-sensitivity troponin I in a healthy blood donor population
- The clinically effective use of cardiac markers by restructuring laboratory profiles at Cardiology wards
- Infectious Diseases
- Lower nasopharyngeal viral load during the latest phase of COVID-19 pandemic in a Northern Italy University Hospital
- SARS-CoV-2 RNA identification in nasopharyngeal swabs: issues in pre-analytics
- Rapid identification of SARS-CoV-2-infected patients at the emergency department using routine testing
- Evaluation of eleven rapid tests for detection of antibodies against SARS-CoV-2
- Development and multicenter performance evaluation of fully automated SARS-CoV-2 IgM and IgG immunoassays
- Letters to the Editor
- Evaluation of seven commercial SARS-CoV-2 RNA detection kits based on real-time polymerase chain reaction (PCR) in China
- Blood sampling after COVID-19 − How to organize large scale phlebotomy services in the post SARS CoV-2 era
- Diagnostic performance of a SARS-CoV-2 IgG/IgM lateral flow immunochromatography assay in symptomatic patients presenting to the emergency department
- Urinalysis parameters for predicting severity in coronavirus disease 2019 (COVID-19)
- Neutrophil-to-lymphocyte ratio predicts the clearance of SARS-CoV-2 RNA in mild COVID-19 patients – a retrospective analysis from Dongxihu Fangcang Hospital in Wuhan, China
- Low levels of total and ionized calcium in blood of COVID-19 patients
- Is “light cannabis” really light? Determination of cannabinoids content in commercial products
- Amino-terminal proB-type natriuretic peptide reference values in umbilical cord blood
- The new era of LED microscopes in immunofluorescence anti-nuclear antibody (ANA) testing
- The centrifuge brake impacts neither routine coagulation assays nor platelet count in platelet-poor plasma
Articles in the same Issue
- Frontmatter
- Editorial
- Measurement uncertainty: light in the shadows
- Review
- Childhood obesity: an overview of laboratory medicine, exercise and microbiome
- Mini review
- The utility of measurement uncertainty in medical laboratories
- Opinion Paper
- Do genetic polymorphisms in angiotensin converting enzyme 2 (ACE2) gene play a role in coronavirus disease 2019 (COVID-19)?
- Opinion Papers
- The current status and future prospects of precision medicine
- Precision medicine in medical oncology: hope, disappointment and reality
- IFCC Papers
- Laboratory practices to mitigate biohazard risks during the COVID-19 outbreak: an IFCC global survey
- Operational considerations and challenges of biochemistry laboratories during the COVID-19 outbreak: an IFCC global survey
- Genetics and Molecular Diagnostics
- Diverse fragment lengths dismiss size selection for serum cell-free DNA: a comparative study of serum and plasma samples
- General Clinical Chemistry and Laboratory Medicine
- Quantification of plasma remdesivir and its metabolite GS-441524 using liquid chromatography coupled to tandem mass spectrometry. Application to a Covid-19 treated patient
- Isotope dilution-LC-MS/MS method for quantification of the urinary cotinine-to-creatinine ratio
- A liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based assay to profile 20 plasma steroids in endocrine disorders
- Assessment of antinuclear antibodies by indirect immunofluorescence assay: report from a survey by the American Association of Medical Laboratory Immunologists
- Evaluation of a novel extended automated particle-based multi-analyte assay for the detection of autoantibodies in the diagnosis of primary biliary cholangitis
- Reference Values and Biological Variations
- Continuous, complete and comparable NT-proBNP reference ranges in healthy children
- Reference-mean-centered statistical quality control
- Hematology and Coagulation
- Top-down and bottom-up approaches for the estimation of measurement uncertainty in coagulation assays
- Cancer Diagnostics
- Tumor-associated exosomal miRNA biomarkers to differentiate metastatic vs. nonmetastatic non-small cell lung cancer
- Analysis of EGFR mutation status in malignant pleural effusion and plasma from patients with advanced lung adenocarcinoma
- Cardiovascular Diseases
- Establishing the 99th percentile of a novel assay for high-sensitivity troponin I in a healthy blood donor population
- The clinically effective use of cardiac markers by restructuring laboratory profiles at Cardiology wards
- Infectious Diseases
- Lower nasopharyngeal viral load during the latest phase of COVID-19 pandemic in a Northern Italy University Hospital
- SARS-CoV-2 RNA identification in nasopharyngeal swabs: issues in pre-analytics
- Rapid identification of SARS-CoV-2-infected patients at the emergency department using routine testing
- Evaluation of eleven rapid tests for detection of antibodies against SARS-CoV-2
- Development and multicenter performance evaluation of fully automated SARS-CoV-2 IgM and IgG immunoassays
- Letters to the Editor
- Evaluation of seven commercial SARS-CoV-2 RNA detection kits based on real-time polymerase chain reaction (PCR) in China
- Blood sampling after COVID-19 − How to organize large scale phlebotomy services in the post SARS CoV-2 era
- Diagnostic performance of a SARS-CoV-2 IgG/IgM lateral flow immunochromatography assay in symptomatic patients presenting to the emergency department
- Urinalysis parameters for predicting severity in coronavirus disease 2019 (COVID-19)
- Neutrophil-to-lymphocyte ratio predicts the clearance of SARS-CoV-2 RNA in mild COVID-19 patients – a retrospective analysis from Dongxihu Fangcang Hospital in Wuhan, China
- Low levels of total and ionized calcium in blood of COVID-19 patients
- Is “light cannabis” really light? Determination of cannabinoids content in commercial products
- Amino-terminal proB-type natriuretic peptide reference values in umbilical cord blood
- The new era of LED microscopes in immunofluorescence anti-nuclear antibody (ANA) testing
- The centrifuge brake impacts neither routine coagulation assays nor platelet count in platelet-poor plasma
